Biohaven BHVN Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biohaven's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biohaven's business segments — net loss?
- Biohaven (BHVN) reported business segments — net loss of -$130.53M in Q1 2026.
- How has Biohaven's business segments — net loss changed year-over-year?
- Biohaven's business segments — net loss increased by 41.1% year-over-year, from -$221.68M to -$130.53M.
- What is the long-term trend for Biohaven's business segments — net loss?
- Over 3 years (2022 to 2025), Biohaven's business segments — net loss has grown at a 9.0% compound annual growth rate (CAGR), from -$570.28M to -$738.82M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result for the reportable segment after all operating expenses, taxes, and non-operating items are deducted. For clinical-stage companies, this metric typically reflects the heavy investment phase of drug development. It serves as the primary measure of the segment's current financial burn rate.